ID: ALA5197464

Max Phase: Preclinical

Molecular Formula: C21H21FN2O4

Molecular Weight: 384.41

Representations

Canonical SMILES:  CCCOc1cc(NC(=O)/C(C#N)=C(/C)O)c(F)cc1-c1cccc(OC)c1

Standard InChI:  InChI=1S/C21H21FN2O4/c1-4-8-28-20-11-19(24-21(26)17(12-23)13(2)25)18(22)10-16(20)14-6-5-7-15(9-14)27-3/h5-7,9-11,25H,4,8H2,1-3H3,(H,24,26)/b17-13-

Standard InChI Key:  BUPBMKIVJYJXQB-LGMDPLHJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 384.41

Molecular Weight (Monoisotopic): 384.1485

AlogP: 4.58

#Rotatable Bonds: 7

Polar Surface Area: 91.58

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.82

CX Basic pKa:

CX LogP: 3.61

CX LogD: 2.02

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.41

Np Likeness Score: -1.15

References

1. Li C, Zhou Y, Xu J, Zhou X, Huang Z, Zeng T, Yang X, Tao L, Gou K, Zhong X, Chen Q, Luo Y, Zhao Y..  (2022)  A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.,  238  [PMID:35640328] [10.1016/j.ejmech.2022.114489]

Source

Source(1):

• Scientific Literature